Explore Our Library of Biomanufacturing Resources & Technical Data

Application Notes

Cellastim S – Reconstitution Application Note

rHSA Reconstitution Video Protocol

Enhanced Cryopreservation of T Cells Using Optibumin®, Recombinant Human Serum Albumin (rHSA)

Exbumin – Stabilizing Virus with Albumin to Improve Yield Application Note

ITS-Animal-Free™ Supplementation for iPSC Expansion and Pluripotency: A Platform Approach for Serum-Free Cell Expansion

Low-DMSO Cryopreservation of MSCs with Optibumin 25 Recombinant Albumin

Recombinant Albumin as a Carrier Protein Improves Cytokine Recovery and Functional Stability at Dilute Concentrations

Reducing Serum-Associated Contaminants from Growth Media in Primary Cell Culture

Safe, Consistent Iron Delivery in Serum-Free Systems with Optiferrin® Recombinant Transferrin

Sustained T Cell Proliferation and Early Memory Retention with OptiLeukin™ 2 Recombinant IL-2

T Cell Cryopreservation Using Exbumin®, Recombinant Human Serum Albumin, and Reduced DMSO

Blog

Beyond Synthetic Surfactants: The Case for Recombinant Human Serum Albumin (rHSA) as an Ideal Alternative to Poloxamer 188

Consistency Is the New Compliance

Controlling Impurities in Cell Culture Media

Cryopreservation Just Got Better with Optibumin® 25

Evolving Challenges in Closed-System Biomanufacturing

How Regulatory Bodies Are Driving the Shift to Animal-Origin-Free Solutions in Cell Therapy and Vaccine Development

Innovative Solutions in Closed-System Biomanufacturing: Exploring the Tools and Technologies Driving Sterility and Efficiency

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

Replacing the “Necessary Evil”: Recombinant Human Serum Albumin as a Chemically Stable Alternative to Polysorbates in Biopharmaceutical Formulation

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

The “Cheap” Albumin Paradox: The Actuarial Cost of Serum Albumin in Biomanufacturing

Why Do Some Biologics Cross the Finish Line—While Others Crash and Burn?

Catalog

InVitria Product Catalog

Data Sheets

Cellastim S – Data Sheet

Exbumin – Data Sheet

ITS Animal-Free – Data Sheet

ITSE Animal-Free – Data Sheet

ITSE+A Animal-Free – Data Sheet

Lacromin – Data Sheet

LIF Leukemia Inhibitory Factor – Data Sheet

Lysobac – Data Sheet

Optibumin 20 – Data Sheet

Optibumin 25 – Data Sheet

Optiferrin – Data Sheet

OptiLeukin 2 – Data Sheet

Journal Articles (DOI Links)

Utilization of Recombinant Albumins in the Expansion of Human T Lymphocytes

Accurate nanoelectrode recording of human pluripotent cell-derived cardiomyocytes for assaying drugs and modeling disease

News

InVitria and Cellevate Partner on Vaccine Manufacturing

Posters

Adherent HEK293t Cells Cultured in Pall’s iCELLis® Bioreactor with OptiPEAK HEK293t Blood-Free Chemically Defined Media Exhibit Robust and Rapid Population Doubling Times

Product Brochures

ITSE AF – Brochure

Optiferrin – Product Brochure

Product Specifications

ITS – Specifications

SDS

Exbumin – Safety Data Sheet

ITS AF – Safety Data Sheet

ITSE AF – Safety Data Sheet

ITSE+A – Safety Data Sheet

Optibumin 25 – Safety Data Sheet

Use Guidelines

Cellastim S – Guidelines for Use

Exbumin – Guidelines for Use

ITS – Guidelines for Use

ITSE AF – Guidelines for Use

ITSE+A – Guidelines for Use

Optiferrin – Guidelines for Use

OptiLeukin 2 – Guidelines for Use

Webinar

Accelerating Vaccine Development Through Use of Blood-Free Components

Why Cell Quality Erodes During Downstream Processing — and How to Prevent It | Webinar

White Papers

Emergence of Blood-Free Recombinant Human Albumin